| Q64100370 | Q64100370 |
| Q64091138 | A Canadian guideline on the use of next-generation sequencing in oncology |
| Q89585666 | A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group |
| Q64113478 | A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab |
| Q89585701 | Accelerating the development of therapeutic strategy for oligometastasis |
| Q90257609 | Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis |
| Q99583003 | Accuracy of lung cancer staging in the multidisciplinary team setting |
| Q99571885 | Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study |
| Q98178765 | Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells |
| Q89622232 | Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases |
| Q89497120 | Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer |
| Q93018439 | Bronchoscopic management of peripheral pulmonary lesions: robotic approach paves the way to the future |
| Q97539154 | Bronchoscopic tissue yield for advanced molecular testing: are we getting enough? |
| Q60301689 | Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status |
| Q90731627 | Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer |
| Q90291712 | Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us? |
| Q92354500 | Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer |
| Q99239307 | Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines |
| Q99582766 | Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma |
| Q91638782 | Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib |
| Q92288092 | Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients |
| Q90169592 | Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis |
| Q97567723 | Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand |
| Q92702613 | Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital |
| Q92877100 | Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis |
| Q99591527 | Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review |
| Q93160518 | Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial |
| Q94450834 | EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors |
| Q99711697 | EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer |
| Q64094655 | Early use of steroids affects immune cells and impairs immunotherapy efficacy |
| Q97524829 | Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial |
| Q90062805 | Ethnic Disparities in PET/CT Utilization at Diagnosis of Non-Small Cell Lung Cancer |
| Q92066104 | External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different |
| Q92466727 | Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer |
| Q90292206 | First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer? |
| Q92469117 | Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study |
| Q90291994 | From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer |
| Q89926672 | Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS |
| Q90400417 | Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements |
| Q89622181 | Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer |
| Q89622486 | Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity |
| Q64994221 | Importance of genetic screens in precision oncology. |
| Q91887235 | Intra-individual variation of circulating tumour DNA in lung cancer patients |
| Q64080812 | It's far better to be alone than to be in bad company |
| Q90312154 | Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib |
| Q89622194 | Lorlatinib: an additional option for ALK-positive non-small cell lung cancer? |
| Q91634657 | Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma |
| Q64094114 | Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time? |
| Q98386283 | New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
| Q90199203 | Non-canonical Raf-1/p70S6K signalling in non-small-cell lung cancer |
| Q91620601 | OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase |
| Q90378344 | Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) |
| Q92179030 | Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies |
| Q91833002 | PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread |
| Q92003504 | PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer |
| Q92140335 | PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study |
| Q90683926 | Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease |
| Q92534185 | Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01) |
| Q97538222 | Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q |
| Q89834907 | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study |
| Q90568070 | Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer |
| Q89746278 | Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution |
| Q91643126 | Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status |
| Q89997722 | Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study |
| Q97518316 | Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group |
| Q90352700 | Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer |
| Q91708481 | Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients |
| Q91737684 | Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway |
| Q92826289 | Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation |
| Q89497167 | Targeting BRAF mutations in non-small cell lung cancer |
| Q98224812 | Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance |
| Q89622529 | The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC |
| Q92605873 | The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer |
| Q91841220 | The electronic nose: emerging biomarkers in lung cancer diagnostics |
| Q90088538 | The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer |
| Q90697039 | Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020 |
| Q64287525 | Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC |
| Q90235689 | Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey |
| Q90623101 | Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology |
| Q91980507 | Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis |
| Q89535783 | Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis |
| Q97518743 | cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation? |